Tuesday, August 15, 2017 9:53:01 AM
1. OXIS Holds Worldwide Exclusive Rights & U.S. Patent For Lead Therapy
OXIS further has licensed exclusive rights to three Antibody-drug conjugates (ADCs) through an agreement made in early 2015 with MultiCell Immunotherapeutics, Inc. MultiCell will prepare these ADCs for further evaluation as prospective therapeutics for the treatment of triple-negative breast cancer, as well as multiple myeloma and associated osteolytic bone disease.
Mr. Cataldo has extensive experience in the biotechnology sector having served as Chairman/CEO of several biotech companies including: MultiCell Technologies, Inc., Calypte Biomedical Corporation, and Senetek, PLC.
https://www.smarteranalyst.com/2016/07/13/one-small-biotech-stock-hold-key-curing-cancer/
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM